C-CAMP, Bangalore, India & AUM Biosciences, Singapore build partnership to further cancer research
C-CAMP, Bangalore, India and AUM Biosciences, Singapore build partnership to develop small molecule candidates as drugs for cancer therapy
By: AUM Biosciences
• This partnership recognizes AUM Biosciences (AUM), as an international incubatee of C-CAMP in the pursuit of developing novel small molecule cancer drugs
• The collaboration will bring together C-CAMP's startup ecosystem and wide academic network with AUM's deep experience in early phase oncology drug development.
The Centre for Cellular and Molecular Platforms (C-CAMP), India's premier bio-innovation hub has signed an agreement with AUM Biosciences, a Singapore- based biotechnology company to strengthen its focus on the pre-clinical development of small-molecules as anti-cancer drugs. The agreement recognises AUM as one of C- CAMP's first international incubatees.
Under this collaboration, C-CAMP will provide AUM with access to ongoing oncology research and drug development in the Indian biotechnology arena through its existing networks, and will pair that with AUM's rich experience in early drug development. C- CAMP will also provide AUM with assistance in IP filing, MTA agreements etc. By tapping on each party's strengths, this symbiotic partnership hopes to advance India-discovered and developed small molecules as drugs for cancer therapy for patients in need across the world.
The partnership creates an avenue for Early Phase commercial exit for C-CAMP's existing startups in the oncology space that share AUM's mandate and vision by making way to license out their technologies. AUM has committed to offer its support to C-CAMP's existing start-ups, in line with Start-up India and Skill India initiatives by the Indian government. AUM Biosciences offers world-class drug development and regulatory strategies designed to rapidly move candidate molecules along the drug development pathway.
Welcoming the formalization of AUM's incubation at C-CAMP, Dr. Taslimarif Saiyed, CEO & Director, C-CAMP said " Cancer continues to be a huge healthcare burden across India
and impacts both livelihood at the personal level and economy at the national. C-Camp is looking forward to having AUM as its international incubatee and supporting AUM's efforts in building new cancer therapeutics. We hope that this partnership will also allow global collaborations for Indian academia and startups.".
"AUM was found on the foundation of developing drugs in "Asia for global". We are committed to working with C-CAMP to support the various initiatives by the Indian government. This partnership will enable us to leverage on AUM's therapeutic innovation expertise to identify, develop novel cancer treatments in Asia," Vishal Doshi, Founder and CEO, AUM Biosciences.
C-CAMP has directly funded, incubated and mentored over 100 start-ups over the last few years and is connected to about 500 startups and entrepreneurs across the country. C-CAMP is an initiative of Department of Biotechnology, Ministry of Science and Technology, Govt. of India. Find more details on
About AUM Biosciences:
Centre for Cellular and Molecular Platforms (C-CAMP) is a member of the Bangalore Life Sciences Cluster (BLiSC) with a mandate to enable cutting-edge life
science research and innovation, and promote life science entrepreneurship. It is India's premier innovation and technology hub as well as one of the largest and most thriving life sciences incubators in the country.
AUM Biosciences is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences will harness the power of precision medicine and digital technologies to enhance the therapeutic and economic value for patients, physicians and our partners. AUM Biosciences partners with research institutions, pharmaceutical companies to acquire oncology drugs that address unmet medical needs. AUM Biosciences focuses on early-stage small molecule
development of innovative medicines for the treatment of Asian-prevalent cancers
prevalent, or has a growing trend in Asia, with an emphasis on small molecule based drug design. AUM Biosciences was founded by industry veterans with over 35 years of combined oncology drug development experience.
For more information, please visit www.aumbiosciences.com
For media queries, please contact:
Dr. Taslimarif Saiyed
Manager, PR & Communications
Meera Jethmal, AUM Biosciences